Dr. Ryter is VP, Manufacturing and Development and Co-Founder of Inimmune. He started his postgraduate synthetic career working at Albany Molecular Research, Inc. In Albany NY. The experience highlighted his ability to adapt and come up to speed quickly on new projects and classes of drug pharmacophores. From alkaloids to opiates to complex heterocycles he worked on projects that included drug discovery and SAR to development and cGMP production, including work in 50-100 L reactors and supervision of pilot plant production.
The opportunity to join Corixa was seen as a new challenge and he delivered as project lead on the development to commercial production of a late-stage, novel TLR4 agonist. Continuing his efforts at GSK, he adapted and contributed to the basic understanding of vaccine adjuvant mechanism of action, developed new methods for preparing complex molecules at scale and seamlessly transitioned projects to contract manufacture. With >18 years of industrial experience, he now leads Product Development at Inimmune.
